Transcriptional regulation by nicotine in dopaminergic neurons

Biochemical Pharmacology

Volumn 86, Issue 8, 2013, Pages 1074-1083

  Henley, Beverley M ^a   Williams, Brian A ^a   Srinivasan, Rahul ^a   Cohen, Bruce N ^a   Xiao, Cheng ^a   Mackey, Elisha D W ^a   Wold, Barbara J ^a   Lester, Henry A ^a  

^a CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Dopamine related genes; Nicotinic acetylcholine receptor; RNA Seq; Substantia nigra pars compacta; Ubiquitin proteasome pathway

Indexed keywords

EID: 84885588241     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.07.031     Document Type: Article

References (71)

1. Research for International Tobacco Control. WHO report on the global tobacco epidemic, 2008: the MPOWER package. World Health Organization; 2008.
2. Barik J, Wonnacott S. Molecular and cellular mechanisms of action of nicotine in the CNS. In: Henningfield J, London E, Pogun S, editors. Nicotine Psychopharmacology. Berlin, Heidelberg: Springer; 2009. p. 173-207.
3. Benowitz NL, Hukkanen J, Jacob 3rd P. Nicotine chemistry, metabolism, kinetics and biomarkers. Handbook of Experimental Pharmacology 2009; 29-60.
4. Drenan RM, Nashmi R, Imoukhuede PI, Just H, McKinney S, Lester HA. Subcellular trafficking pentameric assembly subunit stoichiometry of neuronal nicotinic ACh receptors containing fluorescently-labeled α6 and b3 subunits. Molecular Pharmacology 2008;73:27-41. (Pubitemid 350294194)
5. Nashmi R, Xiao C, Deshpande P, McKinney S, Grady SR, Whiteaker P, et al. Chronic nicotine cell specifically upregulates functional a4 nicotinic receptors: basis for both tolerance in midbrain and enhanced long-Term potentiation in perforant path. The Journal of Neuroscience The Official Journal of the Society for Neuroscience 2007;27:8202-18. (Pubitemid 47219619)
6. Nashmi R, Dickinson ME, McKinney S, Jareb M, Labarca C, Fraser SE, et al. Assembly of a4b2 nicotinic acetylcholine receptors assessed with functional fluorescently labeled subunits: effects of localization, trafficking, and nicotineinduced upregulation in clonal mammalian cells and in cultured midbrain neurons. The Journal of Neuroscience The Official Journal of the Society for Neuroscience 2003;23:11554-67. (Pubitemid 38021283)
7. Srinivasan R, Pantoja R, Moss FJ, Mackey ED, Son CD, Miwa J, et al. Nicotine upregulates a4b2 nicotinic receptors and ER exit sites via stoichiometry-dependent chaperoning. Journal of General Physiology 2011;137:59-79.
8. Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, Labarca C, et al. Nicotine activation of a4 receptors: sufficient for reward, tolerance and sensitization. Science 2004;306:1029-32. (Pubitemid 39482905)
9. Penton RE, Lester RAJ. Cellular events in nicotine addiction. Seminars in Cell & Developmental Biology 2009;20:418-31.
10. Albuquerque EX, Pereira EF, Alkondon M, Rogers SW. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiological Reviews 2009;89:73-120.
11. Brunzell DH, Russell DS, Picciotto MR. In vivo nicotine treatment regulates mesocorticolimbic CREB and ERK signaling in C57Bl/6J mice. Journal of Neurochemistry 2003;84:1431-41. (Pubitemid 36343609)
12. Brunzell DH, Mineur YS, Neve RL, Picciotto MR. Nucleus accumbens CREB activity is necessary for nicotine conditioned place preference. Neuropsychopharmacology Official Publication of the American College of Neuropsychopharmacology 2009;34:1993-2001.
13. Madsen HB, Brown RM, Lawrence AJ. Neuroplasticity in addiction: cellular and transcriptional perspectives. Frontiers in Molecular Neuroscience 2012;5:99.
14. Flatscher-Bader T, Wilce PA. The effect of alcohol and nicotine abuse on gene expression in the brain. Nutrition Research Reviews 2009;22:148-62.
15. Nestler EJ. Transcriptional mechanisms of addiction: role of DFosB. Philosophical Transactions of the Royal Society B Biological Sciences 2008;363:3245.
16. Miwa JM, Freedman R, Lester HA. Neural systems governed by nicotinic acetylcholine receptors: emerging hypotheses. Neuron 2011;70:20-33.
17. Meredith GE, Sonsalla PK, Chesselet M-F. Animal models of Parkinson's disease progression. Acta Neuropathologica 2008;115:385-98.
18. Chesselet M-F, Richter F. Modelling of Parkinson's disease in mice. The Lancet Neurology 2011;10:1108-18.
19. Nestler EJ, Hyman SE, Malenka RC. Molecular neuropharmacology: a foundation for clinical neuroscience. New York: McGraw-Hill, Medical Pub. Division; 2001.
20. Ritz B, Ascherio A, Checkoway H, Marder KS, Nelson LM, Rocca WA, et al. Pooled analysis of tobacco use and risk of Parkinson disease. Archives of Neurology 2007;64:990-7. (Pubitemid 47047999)
21. Thacker EL, O'Reilly EJ, Weisskopf MG, Chen H, Schwarzschild MA, McCullough ML, et al. Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology 2007;68:764-8. (Pubitemid 46667902)
22. Quik M, Wonnacott S. a6b2* and a4b2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease. Pharmacological Reviews 2011;63: 938-66.
23. Quik M, Perez XA, Bordia T. Nicotine as a potential neuroprotective agent for Parkinson's disease. Movement Disorders Official Journal of the Movement Disorder Society 2012;27:947-57.
24. Maggio R, Riva M, Vaglini F, Fornai F, Molteni R, Armogida M, et al. Nicotine prevents experimental Parkinsonism in rodents and induces striatal increase of neurotrophic factors. Journal of Neurochemistry 1998;71:2439-46. (Pubitemid 28531254)
25. Costa G, Abin-Carriquiry JA, Dajas F. Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra. Brain Research 2001;888:336-42. (Pubitemid 32058803)
26. Ryan RE, Ross SA, Drago J, Loiacono RE. Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in a4 nicotinic receptor subunit knockout mice. British Journal of Pharmacology 2001;132:1650-6. (Pubitemid 32397956)
27. Quik M, Parameswaran N, McCallum SE, Bordia T, Bao S, McCormack A, et al. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-Treated primates. Journal of Neurochemistry 2006;98:1866-75. (Pubitemid 44313641)
28. Mercado G, Valdes P, Hetz C. An ERcentric view of Parkinson's disease. Trends in Molecular Medicine 2013;19:165-75.
29. Lindholm D, Wootz H, Korhonen L. ER stress and neurodegenerative diseases. Cell Death and Differentiation 2006;13:385-92.
30. Hoozemans JJ, van Haastert ES, Eikelenboom P, de Vos RA, Rozemuller JM, Scheper W. Activation of the unfolded protein response in Parkinson's disease. Biochemical and Biophysical Research Communications 2007;354:707-11. (Pubitemid 46186242)
31. Doyle KM, Kennedy D, Gorman AM, Gupta S, Healy SJ, Samali A. Unfolded proteins and endoplasmic reticulum stress in neurodegenerative disorders. Journal of Cellular and Molecular Medicine 2011;15:2025-39.
32. Stefani IC, Wright D, Polizzi KM, Kontoravdi C. The role of ER stress-induced apoptosis in neurodegeneration. Current Alzheimer Research 2012;9:373-87.
33. Song L, De Sarno P, Jope RS. Central role of glycogen synthase kinase-3b in endoplasmic reticulum stress-induced caspase-3 activation. The Journal of Biological Chemistry 2002;277:44701-08. (Pubitemid 36159060)
34. Xiao C, Nashmi R, McKinney S, Cai H, McIntosh JM, Lester HA. Chronic nicotine selectively enhances a4b2* nicotinic acetylcholine receptors in the nigrostriatal dopamine pathway. The Journal of Neuroscience The Official Journal of the Society for Neuroscience 2009;29:12428-39.
35. McCallum SE, Parameswaran N, Bordia T, Fan H, McIntosh JM, Quik M. Differential regulation of mesolimbic a3/a6* b2 and a4 b2 nicotinic acetylcholine receptor sites and function after long-Term oral nicotine to monkeys. Journal of Pharmacology and Experimental Therapeutics 2006;318: 381-8. (Pubitemid 43922326)
36. Marks MJ, Rowell PP, Cao JZ, Grady SR, McCallum SE, Collins AC. Subsets of acetylcholine-stimulated 86[Rb]+ efflux and 125[I]-epibatidine binding sites in C57BL/6 mouse brain are differentially affected by chronic nicotine treatment. Neuropharmacology 2004;46:1141-57. (Pubitemid 38529938)
37. Boone DR, Sell SL, Hellmich HL. Laser capture microdissection of enriched populations of neurons or single neurons for gene expression analysis after traumatic brain injury. Journal of Visualized Experiments 2013;74(e50308):1-7.
38. Pietersen CY, Lim MP, Macey L, Woo TU, Sonntag KC. Neuronal type-specific gene expression profiling and laser-capture microdissection. Methods in Molecular Biology (Clifton NJ) 2011;755:327-43.
39. Bonaventure P, Guo H, Tian B, Liu X, Bittner A, Roland B, et al. Nuclei and subnuclei gene expression profiling in mammalian brain. Brain Research 2002;943:38-47. (Pubitemid 34671172)
40. Watkins S. Cryosectioning Current protocols in cytometry/editorial board, J Paul Robinson, managing editor [et al] 2009;Chapter 12:Unit 12 5.
41. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nature Protocols 2012;7:562-78.
42. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols 2009;4:44-57.
43. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Research 2009;37:1-13.
44. Mackey ED, Engle SE, Kim MR, O'Neill HC, Wageman CR, Patzlaff NE, et al. a6* nicotinic acetylcholine receptor expression and function in a visual salience circuit. The Journal of Neuroscience The Official Journal of the Society for Neuroscience 2012;32:10226-37.
45. Briggs CA, Gubbins EJ, Marks MJ, Putman CB, Thimmapaya R, Meyer MD, et al. Untranslated region-dependent exclusive expression of high-sensitivity subforms of a4b2 and a3b2 nicotinic acetylcholine receptors. Molecular Pharmacology 2006;70:227-40.
46. Drenan RM, Grady SR,Whiteaker P,McClure-Begley T,McKinney S,Miwa JM, et al. In vivo activation of midbrain dopamine neurons via sensitized, highaffinity α6 nicotinic acetylcholine receptors. Neuron 2008;60:123-36.
47. Drenan RM, Nashmi R, Imoukhuede P, Just H, McKinney S, Lester HA. Subcellular trafficking, pentameric assembly, and subunit stoichiometry of neuronal nicotinic acetylcholine receptors containing fluorescently labeled α6 and b3 subunits. Molecular Pharmacology 2008;73:27-41. (Pubitemid 350294194)
48. Morris J, Singh JM, Eberwine JH. Transcriptome analysis of single cells. Journal of visualized experiments 2011;50(e2634):1-8.
49. Ramskold D, Luo S, Wang YC, Li R, Deng Q, Faridani OR, et al. Full-length mRNASeq from single-cell levels of RNA and individual circulating tumor cells. Nature Biotechnology 2012;30:777-82.
50. Hnasko TS, Hjelmstad GO, Fields HL, Edwards RH. Ventral tegmental area glutamate neurons: electrophysiological properties and projections. The Journal of Neuroscience The Official Journal of the Society for Neuroscience 2012;32:15076-85.
51. Marks MJ, Pauly JR, Gross SD, Deneris ES, Hermans-Borgmeyer I, Heinemann SF, et al. Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment. The Journal of Neuroscience The Official Journal of the Society for Neuroscience 1992;12:2765-84.
52. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994;78:761-71. (Pubitemid 24294452)
53. Lecker SH, Goldberg AL, Mitch WE. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. Journal of the American Society of Nephrology 2006;17:1807-19. (Pubitemid 44036165)
54. Lennox G, Lowe J, Morrell K, Landon M, Mayer RJ. Anti-ubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of diffuse Lewy body disease. Journal of Neurology Neurosurgery and Psychiatry 1989;52:67-71. (Pubitemid 19043873)
55. Lowe J, McDermott H, Landon M, Mayer RJ, Wilkinson KD. Ubiquitin carboxylterminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. The Journal of Pathology 1990;161:153-60. (Pubitemid 20195792)
56. Ii K, Ito H, Tanaka K, Hirano A. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. Journal of Neuropathology and Experimental Neurology 1997;56: 125-31. (Pubitemid 27461174)
57. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. Chaperone suppression of a-synuclein toxicity in a Drosophila model for Parkinson's disease. Science (New York NY) 2002;295:865-8. (Pubitemid 34118369)
58. McNaught KS, Belizaire R, Jenner P, Olanow CW, Isacson O. Selective loss of 20S proteasome a-subunits in the substantia nigra pars compacta in Parkinson's disease. Neuroscience Letters 2002;326:155-8. (Pubitemid 34722448)
59. Schlossmacher MG, Frosch MP, Gai WP, Medina M, Sharma N, Forno L, et al. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. The American Journal of Pathology 2002;160:1655-67. (Pubitemid 34525646)
60. Cook C, Stetler C, Petrucelli L. Disruption of protein quality control in Parkinson's disease. Cold Spring Harbor Perspectives in Medicine 2012;2:a009423.
61. Kane JK, Konu O, Ma JZ, Li MD. Nicotine coregulates multiple pathways involved in protein modification/degradation in rat brain. Brain Research Molecular Brain Research 2004;132:181-91. (Pubitemid 39586760)
62. Nelson SB, Hempel C, Sugino K. Probing the transcriptome of neuronal cell types. Current Opinion in Neurobiology 2006;16:571-6. (Pubitemid 44466396)
63. Simunovic F, Yi M, Wang Y, Macey L, Brown LT, Krichevsky AM, et al. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. Brain A Journal of Neurology 2009;132: 1795-809.
64. Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, et al. PGC-1a, a potential therapeutic target for early intervention in Parkinson's disease. Science Translational Medicine 2010;2:52ra73.
65. Shalek AK, Satija R, Adiconis X, Gertner RS, Gaublomme JT, Raychowdhury R, et al. Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells. Nature 2013;498:236-40.
66. Bengtsson M, Stahlberg A, Rorsman P, Kubista M. Gene expression profiling in single cells from the pancreatic islets of Langerhans reveals lognormal distribution of mRNA levels. Genome Research 2005;15:1388-92. (Pubitemid 41400905)
67. Raj A, van Oudenaarden A. Single-molecule approaches to stochastic gene expression. Annual Review of Biophysics 2009;38:255-70.
68. Kalisky T, Blainey P, Quake SR. Genomic analysis at the single-cell level. Annual Review of Genetics 2011;45:431-45.
69. Feinerman O, Jentsch G, Tkach KE, Coward JW, Hathorn MM, Sneddon MW, et al. Single-cell quantification of IL-2 response by effector and regulatory T cells reveals critical plasticity in immune response. Molecular Systems Biology 2010;6:437.
70. Cohen AA, Geva-Zatorsky N, Eden E, Frenkel-Morgenstern M, Issaeva I, Sigal A, et al. Dynamic proteomics of individual cancer cells in response to a drug. Science (New York NY) 2008;322:1511-6.
71. Klink R, de Kerchove d'Exaerde A, Zoli M, Changeux JP. Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. The Journal of Neuroscience The Official Journal of the Society for Neuroscience 2001;21:1452-63. (Pubitemid 32182187)